Laplace Device for Severe Tricuspid Regurgitation

Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement System

Recruiting N/A Interventional Study
Severe Tricuspid Valve Regurgitation Tricuspid Valve Regurgitation Tricuspid Valve Disease Cardiovascular Diseases (CVD) Heart Valve Diseases Tricuspid Valve Insufficiency Severe Heart Valve Disease Symptomatic Tricuspid Regurgitation
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 90
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
700 (estimated)
Sponsor
Laplace Interventional, Inc · Industry
Who this trial is looking for

This trial is looking for people with severe tricuspid regurgitation who still have symptoms despite treatment. Participants will be treated with a new device and will need to follow up after the procedure.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 18 and 90 years old.
  • I have severe tricuspid regurgitation.
  • I have symptoms despite treatment for at least 30 days.
  • I am considered suitable for the device by my heart team.
  • I agree to follow all study requirements.
  • I am anatomically suitable for the Laplace device.

You may not be able to join if

  • My life expectancy is less than 12 months.
  • I need surgery within 30 days after the study procedure.
  • I have severe kidney issues.
  • I have used illegal drugs in the last 5 years.
  • I have had a stroke within the last 90 days.
  • I am pregnant or planning to be pregnant in the next 12 months.
  • I am involved in another similar study.
  • I am not suitable for the Laplace device.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The objective of this clinical study is to assess the safety and efficacy of the Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System for the treatment of symptomatic subjects with at least severe tricuspid regurgitation (TR).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 18 - 90 years of age at the time of the study procedure. * Symptomatic TR despite being adequately treated with OMT by the Local Heart Team for at least 30 days prior to the time of study consent. * Severe, massive or torrential tricuspid regurgitation determined by qualifying…
Contacts

Ryan Gladney

763-710-3539

clinical@laplaceint.com

CONTACT